Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AsfiledCriticalNovo Nordisk As
Publication of AR114539A1publicationCriticalpatent/AR114539A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente se refiere a anticuerpos procoagulantes biespecíficos capaces de unirse al Factor de coagulación IX (FIX) y/o su forma activada el Factor IXa (FIXa), y al Factor X (FX) y/o su forma activada el Factor Xa (FXa) y promover la activación de FX por FIXa, los anticuerpos que unen sus epítopos o partes de los mismos y los métodos y la composición para tratar sujetos que padecen una coagulopatía tal como la hemofilia A, así como también kits, métodos de fabricación y métodos de uso.This refers to bispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and / or its activated form Factor IXa (FIXa), and to Factor X (FX) and / or its activated form Factor Xa (FXa ) and promote the activation of FX by FIXa, the antibodies that bind its epitopes or parts thereof, and the methods and composition for treating subjects suffering from a coagulopathy such as hemophilia A, as well as kits, manufacturing methods and methods of use.